Hsp90 governs dispersion and drug resistance of fungal biofilms

PLoS Pathogens

Volumn 7, Issue 9, 2011, Pages

  Robbins, Nicole ^a   Uppuluri, Priya ^b   Nett, Jeniel ^c   Rajendran, Ranjith ^d   Ramage, Gordon ^d   Lopez Ribot, Jose L ^b   Andes, David ^c   Cowen, Leah E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CASPOFUNGIN; FLUCONAZOLE; GELDANAMYCIN; GLUCAN; HEAT SHOCK PROTEIN 90; MICAFUNGIN; TACROLIMUS; ANTIFUNGAL AGENT; ECHINOCANDIN; FUNGAL PROTEIN; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BIOFILM; CANDIDA ALBICANS; CANDIDIASIS; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CONTROLLED STUDY; DISPERSION; IN VITRO STUDY; INHIBITION KINETICS; NONHUMAN; PLANKTON; PROTEIN DEPLETION; PROTEIN FUNCTION; RAT; ANTIFUNGAL RESISTANCE; CONFOCAL MICROSCOPY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; SCANNING ELECTRON MICROSCOPY;

ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; RATTUS;

ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; AZOLES; BIOFILMS; CALCINEURIN; CANDIDA ALBICANS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FLUCONAZOLE; FUNGAL PROTEINS; GENE EXPRESSION REGULATION, FUNGAL; HSP90 HEAT-SHOCK PROTEINS; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, SCANNING;

EID: 80053455899     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002257     Document Type: Article

References (61)

1. Cowen LE, Steinbach WJ, (2008) Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell 7: 747-764.
2. Pfaller MA, Diekema DJ, (2010) Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 36: 1-53.
3. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, et al. (2001) Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 33: 641-647.
4. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, et al. (2005) The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 41: 1232-1239.
5. Pfaller MA, Diekema DJ, (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20: 133-163.
6. Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, et al. (2002) The direct cost and incidence of systemic fungal infections. Value Health 5: 26-34.
7. Lin SJ, Schranz J, Teutsch SM, (2001) Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32: 358-366.
8. Lupetti A, Danesi R, Campa M, Del Tacca M, Kelly S, (2002) Molecular basis of resistance to azole antifungals. Trends Mol Med 8: 76-81.
9. Ostrosky-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH, (2010) An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov 9: 719-727.
10. Anderson JB, (2005) Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat Rev Microbiol 3: 547-556.
11. Cowen LE, (2008) The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. Nat Rev Microbiol 6: 187-198.
12. Perea S, Lopez-Ribot JL, Kirkpatrick WR, McAtee RK, Santillan RA, et al. (2001) Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 45: 2676-2684.
13. Shapiro RS, Robbins N, Cowen LE, (2011) Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev 75: 213-267.
14. Balashov SV, Park S, Perlin DS, (2006) Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 50: 2058-2063.
15. Park S, Kelly R, Kahn JN, Robles J, Hsu MJ, et al. (2005) Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 49: 3264-3273.
16. Finkel JS, Mitchell AP, (2011) Genetic control of Candida albicans biofilm development. Nat Rev Microbiol 9: 109-118.
17. Ramage G, Mowat E, Jones B, Williams C, Lopez-Ribot J, (2009) Our current understanding of fungal biofilms. Crit Rev Microbiol 35: 340-355.
18. Blankenship JR, Mitchell AP, (2006) How to build a biofilm: a fungal perspective. Curr Opin Microbiol 9: 588-594.
19. d'Enfert C, (2006) Biofilms and their role in the resistance of pathogenic Candida to antifungal agents. Curr Drug Targets 7: 465-470.
20. Nobile CJ, Mitchell AP, (2006) Genetics and genomics of Candida albicans biofilm formation. Cell Microbiol 8: 1382-1391.
21. Ramage G, Martinez JP, Lopez-Ribot JL, (2006) Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res 6: 979-986.
22. Kojic EM, Darouiche RO, (2004) Candida infections of medical devices. Clin Microbiol Rev 17: 255-267.
23. Viudes A, Peman J, Canton E, Ubeda P, Lopez-Ribot JL, et al. (2002) Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis 21: 767-774.
24. Seidler MJ, Salvenmoser S, Müller F-MC, (2008) Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells. Antimicrob Agents Chemother 52: 4130-4136.
25. Perumal P, Mekala S, Chaffin WL, (2007) Role for cell density in antifungal drug resistance in Candida albicans biofilms. Antimicrob Agents Chemother 51: 2454-2463.
26. Ramage G, Bachmann S, Patterson TF, Wickes BL, Lopez-Ribot JL, (2002) Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother 49: 973-980.
27. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA, (2003) Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun 71: 4333-4340.
28. Nett J, Lincoln L, Marchillo K, Massey R, Holoyda K, et al. (2007) Putative role of beta-1,3 glucans in Candida albicans biofilm resistance. Antimicrob Agents Chemother 51: 510-520.
29. Nett JE, Sanchez H, Cain MT, Andes DR, (2010) Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. J Infect Dis 202: 171-175.
30. Kumamoto CA, (2005) A contact-activated kinase signals Candida albicans invasive growth and biofilm development. Proc Natl Acad Sci U S A 102: 5576-5581.
31. Uppuluri P, Nett J, Heitman J, Andes D, (2008) Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother 52: 1127-1132.
32. Taipale M, Jarosz DF, Lindquist S, (2010) HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 11: 515-528.
33. Pearl LH, Prodromou C, (2006) Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 75: 271-294.
34. Cowen LE, Singh SD, Köhler JR, Collins C, Zaas AK, et al. (2009) Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci USA 106: 2818-2823.
35. Pallavi R, Roy N, Nageshan RK, Talukdar P, Pavithra SR, et al. (2010) Heat shock protein 90 as a drug target against protozoan infections: biochemical characterization of HSP90 from Plasmodium falciparum and Trypanosoma evansi and evaluation of its inhibitor as a candidate drug. J Biol Chem 285: 37964-37975.
36. Shahinas D, Liang M, Datti A, Pillai DR, (2010) A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90. J Med Chem 53: 3552-3557.
37. Cowen LE, Lindquist S, (2005) Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309: 2185-2189.
38. Singh SD, Robbins N, Zaas AK, Schell WA, Perfect JR, et al. (2009) Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog 5: e1000532.
39. LaFayette SL, Collins C, Zaas AK, Schell WS, Betancourt-Quiroz M, et al. (2010) PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90. PLoS Pathog 6: e1001069.
40. Noble SM, French S, Kohn LA, Chen V, Johnson AD, (2010) Systematic screens of a Candida albicans homozygous deletion library decouple morphogenetic switching and pathogenicity. Nat Genet 42: 590-598.
41. Shapiro RS, Uppuluri P, Zaas AK, Collins C, Senn H, et al. (2009) Hsp90 orchestrates temperature-dependent Candida albicans morphogenesis via Ras1-PKA signaling. Curr Biol 19: 621-629.
42. Ramage G, VandeWalle K, Lopez-Ribot JL, Wickes BL, (2002) The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol Lett 214: 95-100.
43. Ramage G, Vande Walle K, Wickes BL, Lopez-Ribot JL, (2001) Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 45: 2475-2479.
44. Andes D, Nett J, Oschel P, Albrecht R, Marchillo K, et al. (2004) Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect Immun 72: 6023-6031.
45. Uppuluri P, Pierce CG, Thomas DP, Bubeck SS, Saville SP, et al. (2010) The transcriptional regulator Nrg1p controls Candida albicans biofilm formation and dispersion. Eukaryot Cell 9: 1531-1537.
46. Uppuluri P, Chaturvedi AK, Srinivasan A, Banerjee M, Ramasubramaniam AK, et al. (2010) Dispersion as an important step in the Candida albicans biofilm developmental cycle. PLoS Pathog 6: e1000828.
47. Uppuluri P, Chaturvedi AK, Lopez-Ribot JL, (2009) Design of a simple model of Candida albicans biofilms formed under conditions of flow: development, architecture, and drug resistance. Mycopathologia 168: 101-109.
48. Uppuluri P, Lopez-Ribot JL, (2011) An easy and economical in vitro method for the formation of Candida albicans biofilms under continuous conditions of flow. Virulence 1: 483-487.
49. Cowen LE, Carpenter AE, Matangkasombut O, Fink GR, Lindquist S, (2006) Genetic architecture of Hsp90-dependent drug resistance. Eukaryot Cell 5: 2184-2188.
50. Young JC, Moarefi I, Hartl FU, (2001) Hsp90: a specialized but essential protein-folding tool. J Cell Biol 154: 267-273.
51. Garcia-Sanchez S, Aubert S, Iraqui I, Janbon G, Ghigo JM, et al. (2004) Candida albicans biofilms: a developmental state associated with specific and stable gene expression patterns. Eukaryot Cell 3: 536-545.
52. Nobile CJ, Nett JE, Hernday AD, Homann OR, Deneault JS, et al. (2009) Biofilm matrix regulation by Candida albicans Zap1. PLoS Biol 7: e1000133.
53. Usmani SZ, Bona R, Li Z, (2009) 17 AAG for HSP90 inhibition in cancer-from bench to bedside. Curr Mol Med 9: 654-664.
54. Kim YS, Alarcon SV, Lee S, Lee MJ, Giaccone G, et al. (2009) Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem 9: 1479-1492.
55. Kaneko Y, Ohno H, Fukazawa H, Murakami Y, Imamura Y, et al. (2010) Anti-Candida-biofilm activity of micafungin is attenuated by voriconazole but restored by pharmacological inhibition of Hsp90-related stress responses. Med Mycol 48: 606-612.
56. Trepel J, Mollapour M, Giaccone G, Neckers L, (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10: 537-549.
57. Richard ML, Nobile CJ, Bruno VM, Mitchell AP, (2005) Candida albicans biofilm-defective mutants. Eukaryot Cell 4: 1493-1502.
58. Mowat E, Butcher J, Lang S, Williams C, Ramage G, (2007) Development of a simple model for studying the effects of antifungal agents on multicellular communities of Aspergillus fumigatus. J Med Microbiol 56: 1205-1212.
59. Burt ET, Daly R, Hoganson D, Tsirulnikov Y, Essmann M, et al. (2003) Isolation and partial characterization of Hsp90 from Candida albicans. Ann Clin Lab Sci 33: 86-93.
60. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, et al. (2004) Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 39: 199-205.
61. McCourtie J, Douglas LJ, (1985) Extracellular polymer of Candida albicans: isolation, analysis and role in adhesion. J Gen Microbiol 131: 495-503.